Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Aligos Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 40
- +4 vs. Q3 2023
- Shares held
- 45.4M
- +19.6M (+76.2%) vs. Q3 2023
- Total value
- $30.1M
- +$10.9M (+56.6%) vs. Q3 2023
- New holders
- 9
- 8 more added
- Sold out
- 5
- 8 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 6,833,875 | $4.54M | 0.12% | +6,833,875 | New |
| EcoR1 Capital, LLC | 6,389,468 | $4.24M | 0.11% | +2,441,108+61.8% | Added |
| Deep Track Capital, LP | 6,102,770 | $4.05M | 0.14% | +6,102,770 | New |
| Vivo Capital, LLC | 3,547,030 | $2.36M | 0.19% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 2,882,216 | $1.91M | 0.01% | +2,882,216 | New |
| Altitude Crest Partners Inc. | 2,844,681 | $1.89M | 1.26% | +2,844,681 | New |
| Versant Venture Management, LLC | 2,320,381 | $1.54M | 0.40% | 00.0% | Unchanged |
| Tang Capital Management LLC | 2,189,847 | $1.45M | 0.13% | −1,139,201−34.2% | Reduced |
| Baker Bros. Advisors LP | 2,076,400 | $1.38M | 0.02% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,906,191 | $1.27M | 0.03% | −403,573−17.5% | Reduced |
| Opaleye Management Inc. | 1,297,000 | $861.2K | 0.23% | +1,297,000 | New |
| Newtyn Management, LLC | 1,255,000 | $833.3K | 0.16% | +335,000+36.4% | Added |
| Bank of America Corp | 1,147,762 | $762.1K | 0.00% | −2,465−0.2% | Reduced |
| Vanguard Group Inc | 1,011,651 | $671.7K | 0.00% | +1,034+0.1% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $493.5K | 0.13% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 668,512 | $443.9K | 0.14% | +36,625+5.8% | Added |
| Acadian Asset Management LLC | 559,367 | $370.0K | 0.00% | −5,348−0.9% | Reduced |
| Renaissance Technologies LLC | 489,960 | $325.0K | 0.00% | +168,600+52.5% | Added |
| Geode Capital Management, LLC | 321,044 | $213.2K | 0.00% | +79,541+32.9% | Added |
| BlackRock Inc. | 296,139 | $196.6K | 0.00% | −820−0.3% | Reduced |
| State Street Corp | 97,423 | $64.7K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 92,000 | $61.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 53,968 | $35.8K | 0.00% | +14,617+37.1% | Added |
| Charles Schwab Investment Management Inc | 31,383 | $20.8K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 28,705 | $19.1K | 0.00% | −63,102−68.7% | Reduced |
| XTX Topco Ltd | 25,743 | $17.1K | 0.00% | +25,743 | New |
| Choate Investment Advisors | 24,000 | $15.9K | 0.00% | 00.0% | Unchanged |
| HarbourVest Partners LLC | 18,783 | $12.5K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 18,728 | $12.4K | 0.00% | +18,728 | New |
| Two Sigma Investments, LP | 18,624 | $12.4K | 0.00% | −4,300−18.8% | Reduced |
| CWM, LLC | 16,891 | $11.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 14,739 | $9.79K | 0.00% | +14,739 | New |
| Zullo Investment Group, Inc. | 13,000 | $8.63K | 0.00% | +13,000 | New |
| Creative Planning | 10,050 | $6.67K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2,000 | $1.33K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 677 | $450 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 293 | $195 | 0.00% | +98+50.3% | Added |
| ZRC Wealth Management, LLC | 100 | $75 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 441 | $0 | 0.00% | −644,112−99.9% | Reduced |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −1,223,278−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,432−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −653−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −37−100.0% | Sold out |